Health & Biotech Neurotech completes recruitment in Phase 2/3 autism spectrum disorder trial December 19, 2023 Clinical-stage biopharmaceutical development company Neurotech International is on track to deliver results for its Phase 2/3 NTIASD2 clinical trial for children… ASX Health Stocks: dorsaVi up 27pc on US deals, Starpharma reports positive outcome on Phase 2 trial December 19, 2023 Starpharma reports positive outcome on Phase 2 trial, dorsaVi up almost 30pc on US deals, and Tissue Repair gets third… ‘World first’: AdAlta’s i-body platform a breakthrough for malaria treatment December 19, 2023 AdAlta, in collaboration with La Trobe University, has made a world-first breakthrough using its i-body® platform which could provide potential… ASX Health stocks: Neuren soars 30% in early Christmas present after Phase 2 trial success December 18, 2023 Neuren Pharmaceuticals soars 30% after Phase 2 trial shows significant improvements in Phelan-McDermid syndrome. ScoPo’s Powerplays: ASX healthcare up as ‘rising tide lifts all boats’ December 15, 2023 ASX health stocks are up this week in line with broader markets this week as Sigma Healthcare (ASX:SIG) soars on… ASX Health Stocks: ACCC shoots down merger between pathology stocks ACL and Healius December 15, 2023 ACL's proposed acquisition of Healius shot down by ACCC. The ACCC says a merger could lessen competition in Australian pathology… Check Up: Introducing the Brain Atlas, the largest map of the human brain. And recent ASX biotech winners December 15, 2023 Brain mapping research is taking off with publication of a Brain Atlas. Stockhead looks at ASX stocks that focus on… AdAlta on track for trial readout in Q1 2024 after $1.65m cap raise December 14, 2023 1AD’s Phase 1 extension trial of its lead asset AD-214 in Idiopathic Pulmonary Fibrosis (IPF) remains on track for final readout in… ASX Health Stocks: Mach7 signs $10m deal; Volpara agrees to $300m takeover from South Korean outfit December 14, 2023 Medical imaging device company Mach7 signs five-year $10m deal. lArgenica Therapeutics is ready to commence Phase 2 clinical trial. Argenica on track to commence patient dosing for Phase 2 stroke clinical trial in Q1 December 14, 2023 Argenica Therapeutics is progressing its Phase 2 clinical trial in acute ischaemic stroke (AIS) patients, with the manufacturing of its… Next» « Previous